Table 1.

Clinical Characteristics of 100 Patients Who Received Allogeneic Transplants With or Without Subsequent Infusions of Prophylactic Cytotoxic T Cells

Study Group (n = 39) Control Group (n = 61)
Age at treatment (mean and range) 9.5 yr (9 mo to 20 yr) 9.8 yr (8 mo to 23 yr)  
Male:female  18:21  33:28 
Diagnostic category  
 Standard risk* 19  24 
 High risk-151 20  37  
Type of transplant received 
 Mismatched family member  
  5/6 match   2  11 
  4/6 match   3   9  
  3/6 match   1   3 
 Unrelated donor  
  6/6 match  20  22  
  5/6 match  13  16  
No. of developing EBV lymphoma   0 7 (2 mismatched family member, 5 unrelated donor)  P = .03 
Study Group (n = 39) Control Group (n = 61)
Age at treatment (mean and range) 9.5 yr (9 mo to 20 yr) 9.8 yr (8 mo to 23 yr)  
Male:female  18:21  33:28 
Diagnostic category  
 Standard risk* 19  24 
 High risk-151 20  37  
Type of transplant received 
 Mismatched family member  
  5/6 match   2  11 
  4/6 match   3   9  
  3/6 match   1   3 
 Unrelated donor  
  6/6 match  20  22  
  5/6 match  13  16  
No. of developing EBV lymphoma   0 7 (2 mismatched family member, 5 unrelated donor)  P = .03 

*Chronic myeloid leukemia in chronic or accelerated phase; acute myeloid or lymphoblastic leukemia in first or second remission; and metabolic storage diseases.

F0-151

Chronic myeloid leukemia in or after blast crisis; acute myeloid or lymphoblastic leukemia in relapse or greater than second remission; myelodysplasia; secondary acute myeloid leukemia; and familial erythrophagocytic lymphohistiocytosis.

or Create an Account

Close Modal
Close Modal